Andrei Biţă, Ion Romulus Scorei, Marvin A. Soriano‐Ursúa, Cătălina Gabriela Pisoschi, Cristina Elena Biță, Laura Dincă, Simona Ștefănescu, Maria-Victoria Racu, Iurie Pînzaru, Cristina Florescu, Diana-Ruxandra Hădăreanu, Cristian Adrian Siloşi, Johny Neamţu, Dan Ionuț Gheonea, George Dan Mogoşanu, Marian Valentin Zorilă
Boron (B) remains one of the least understood trace elements in human nutrition. Traditionally regarded as non-essential, its biological role has been reevaluated in light of emerging microbiome research. We provide a narrative synthesis of mechanistic, preclinical, and clinical studies to assess whether the colonic actions of B meet accepted criteria for nutritional essentiality. This review revisits B bioavailability through a dual-pathway framework distinguishing plasma-accessible boron (PAB)-small, fully absorbable species with transient systemic effects-from microbiota-accessible boron complexes (MABCs)-indigestible conjugates that reach the colon intact. Evidence indicates that PAB exerts short-term metabolic modulation, whereas MABCs act as prebiotic cofactors that stabilize microbial quorum sensing (autoinducer-2-borate; AI-2B), reinforce the colonic mucus barrier through borate-diol crosslinking, and support host-microbiota symbiosis. Deficiency or low intake of MABCs leads to dysbiosis, barrier fragility, and low-grade inflammation along gut-organ axes-effects reversible by MABC-rich diets. Analytical and clinical tools are proposed to discriminate between PAB and MABC pathways, including fecal B/speciation, AI-2B assays, and mucus-penetration markers. Recognizing B's essentiality as a microbiota-dependent nutrient reframes its nutritional assessment, guiding future dietary guidelines and prebiotic design toward the microbiome-mucus interface.